HKG:3347

Tigermed Controlling Shareholders Face Fines Over Disclosure Violations

Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) said two directors and controlling shareholders face proposed fines of 500,000 yuan each over historical shareholding disclosure violations, according to a Sept. 11 Hong Kong bourse filing.Ye Xiaoping and Cao Xiaochun received warning letters and advance notices of administrative penalties from the Zhejiang Regulatory Bureau of the China Securities Regulatory Commission.The regulator said the pair failed to timely disclose changes in their combined A-share holdings that reached 5% in September 2019 and a subsequent 1% reduction in December 2022.

Jefferies Adjusts Hangzhou Tigermed Consulting's Price Target to HK$45 From HK$55, Keeps at Hold

Tigermed Consulting Swings to H1 Attributable Loss; Revenue Up

Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) reported 413.2 million yuan in loss attributable to owners for the first half, compared with an attributable profit of 383.3 million yuan a year ago, a Friday bourse filing showed.Loss per share for the period was 0.48 yuan, whereas the company had made earnings per share of 0.45 yuan in the prior-year period.For the six months ended June 30, operating revenue was 3.71 billion yuan, versus 3.25 billion yuan previously, the Chinese medical laboratory operator said.

Tigermed Consulting to Pay 2025 Dividend on July 31

Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) will pay a dividend of around HK$1.45 per 10 shares for the year 2025, according to a Tuesday Hong Kong bourse filing.Shares of the Chinese medical laboratory operator were down nearly 2% in Wednesday afternoon trading.The dividend will be paid July 31 to shareholders of record June 26.

Hangzhou Tigermed Consulting Names New Chairman, CFO

Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) elected Ye Xiaoping as chairman and appointed Yang Chengcheng as chief financial officer, effective Tuesday, according to a same-day Hong Kong bourse filing.The clinical trial services provider also appointed Peng Yifei as chief operating officer and Wu Hao as co-president.

Tigermed Consulting Stock Tumbles as Directors Face Regulatory Probe

Hangzhou Tigermed Consulting (HKG:3347) said its directors and controlling shareholders, Ye Xiaoping and Cao Xiaochun, are being investigated in China, according to a Tuesday filing with the Hong Kong bourse.The clinical trial services provider's shares fell nearly 6% in morning trade on Wednesday.China's Securities Regulatory Commission launched a probe into Ye and Cao for possible violations regarding information disclosure related to changes in the company's shareholding, the filing said.Tigermed Consulting said the probe will not affect its day-to-day operations.

Tigermed Consulting's Q1 Profit Slides 70%

Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) recorded a 70% decline in attributable profit in the first quarter of 2026 to 49 million yuan from 165.5 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.Earnings per share slipped to 0.06 yuan from 0.19 yuan in the corresponding period of the previous fiscal year.The medical laboratory company's revenue jumped 15% to 1.8 billion yuan from 1.56 billion yuan in the year-ago period.